Director Bakari Sellers gets 1,572 cbdMD (YCBD) RSUs as board grant

Rhea-AI Filing Summary

Sellers Bakari T. reported acquisition or exercise transactions in this Form 4 filing.

cbdMD, Inc. director Bakari T. Sellers reported an equity compensation grant of 1,572 shares of common stock in the form of restricted stock units at no cash cost per share. Following this award, his directly held equity position increased to 4,324 shares.

The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, aligning compensation with ongoing Board service under cbdMD’s 2021 or 2025 Equity Compensation Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sellers Bakari T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,572	$0.00	--

Holdings After Transaction: Common Stock — 4,324 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 1,572 units Grant price per share: $0.0000 per share Shares held after grant: 4,324 shares +1 more

4 metrics

RSUs granted 1,572 units Restricted stock unit award to director on April 14, 2026

Grant price per share $0.0000 per share Reported transaction price for RSU award

Shares held after grant 4,324 shares Total direct holdings following the transaction

Vesting dates June 30, 2026 to March 31, 2027 Quarterly vesting schedule for RSUs

Key Terms

restricted stock units, Section 16(b), Rule 16b-3, Equity Compensation Plan

4 terms

restricted stock units financial

"Represents restricted stock units. Each restricted stock unit represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Section 16(b) regulatory

"The grant was exempt from Section 16(b) under the Securities Exchange Act"

A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.

Rule 16b-3 regulatory

"by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Equity Compensation Plan financial

"issued under the 2021 or 2025 Equity Compensation Plan as compensation"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sellers Bakari T.

(Last) (First) (Middle)

2101 WESTINGHOUSE BLVD. SUITE A

(Street)

CHARLOTTE NORTH CAROLINA 28273

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
cbdMD, Inc. [ YCBD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	04/14/2026		A		1,572	A	$0	4,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted stock units vest quarterly on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. The restricted stock units were issued under the 2021 or 2025 Equity Compensation Plan as compensation to the Reporting Person for services on the Issuer's Board of Directors.

	/s/ Bakari Sellers	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did cbdMD (YCBD) director Bakari T. Sellers receive in this Form 4?

Bakari T. Sellers received 1,572 restricted stock units of cbdMD common stock as equity compensation. Each unit represents one share, granted at no cash cost, and is tied to his ongoing service on the company’s Board of Directors under an equity compensation plan.

How many cbdMD (YCBD) shares does Bakari T. Sellers hold after this grant?

After the reported grant, Bakari T. Sellers directly holds 4,324 shares of cbdMD common stock. This total includes the newly awarded 1,572 restricted stock units, which convert into shares as they vest over the specified quarterly schedule through March 31, 2027.

How do the cbdMD (YCBD) restricted stock units granted to Sellers vest?

The 1,572 restricted stock units granted to Bakari T. Sellers vest in four quarterly installments. Vesting dates are June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, aligning the award with his continuing Board service over that time frame.

Did Bakari T. Sellers pay cash for the cbdMD (YCBD) shares in this transaction?

No, Bakari T. Sellers did not pay cash for these shares. The 1,572 restricted stock units were granted at a reported price of $0.0000 per share, reflecting a stock-based compensation award approved by cbdMD’s Compensation, Corporate Governance and Nominating Committee.

Under which plan were the cbdMD (YCBD) restricted stock units issued to Sellers?

The restricted stock units were issued under cbdMD’s 2021 or 2025 Equity Compensation Plan. These plans provide stock-based compensation to directors, and this particular grant compensates Bakari T. Sellers for his services on the company’s Board of Directors.

Why is the cbdMD (YCBD) equity grant to Bakari T. Sellers exempt from Section 16(b)?

The grant is exempt from Section 16(b) short-swing profit rules because it was approved in advance under SEC Rule 16b-3. cbdMD’s Compensation, Corporate Governance and Nominating Committee, composed of three non-employee directors, approved the award, qualifying it for this exemption.